Style Editor Docs
RadioGel™
Precision Radionuclide Therapy (PRnT)
Research (White Papers)
US FDA IDE Application Updates
US FDA IDE Pre-Submission Process
Human Clinical Trials
IsoPet®
Regional Clinics
IsoPet® Therapy Dog • Cat Application
IsoPet® Therapy Equine Application
IsoPet® Therapy Pets
Research (White Papers)
Veterinarians
Animal Studies
Canine Studies
Feline Studies
Our IsoPet® Mission
About Us
Management & Consultants
Advisory Boards
Contact - RadioGel™ | IsoPet®
Blog
Vivos Inc.
Press Releases
Board of Directors
SEC Filings
Contact - Investor Relations
Contact Us
RadioGel™
Precision Radionuclide Therapy (PRnT)
Research (White Papers)
US FDA IDE Application Updates
US FDA IDE Pre-Submission Process
Human Clinical Trials
IsoPet®
Regional Clinics
IsoPet® Therapy Dog • Cat Application
IsoPet® Therapy Equine Application
IsoPet® Therapy Pets
Research (White Papers)
Veterinarians
Animal Studies
Canine Studies
Feline Studies
Our IsoPet® Mission
About Us
Management & Consultants
Advisory Boards
Contact - RadioGel™ | IsoPet®
Blog
Vivos Inc.
Press Releases
Board of Directors
SEC Filings
Contact - Investor Relations
Vivos Inc.
SEC Filings
SEC Filings - Vivos, Inc.
trading symbol: OTCQB: RDGL
</ iframe
Vivos Form 10-K December 31, 2022
Vivos Inc. – December 31, 2022 Annual Report
Vivos Form 10-K 2022.pdf
Adobe Acrobat Document
2.5 MB
Download
Press Releases
Board of Directors
SEC Filings
Contact - Investor Relations
Scroll to top